Sofinnova Venture Partners
Venture capitalMenlo Park
Fund manager profile
Sofinnova Venture Partners is a venture fund manager based in Menlo Park. SEC filings show 2 venture funds on record, most recently Sofinnova Venture Partners X, L.P. ($650M offering) filed August 2016.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
What they invest in
from 5 of 5 portfolio companiesBiotech ×4Healthtech ×3Medical Devices ×2Digital Health ×1
HQs:United States×4
Investments · 5 tracked
founders shown can be your intro pathBy year:2020 · 22017 · 22015 · 15 dated
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.
BiotechHealthtechMedical DevicesWayne, US
Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)Joseph Monahan(Executive Officer)Hugh Davis(Executive Officer, Director)James Loerop(Executive Officer)
Board seatAnand Mehra· per SEC Form D · $11.4M raise · filed Apr 2020
Co-investorsAisling CapitalAPERTURE Venture PartnersF-Prime CapitalForesite CapitalRA CapitalSofinnova Ventures+1 more
Developing broad-spectrum antifungal agents for invasive fungal infections.
BiotechSan Diego, US
Mitchell Mutz(Executive Officer, Director)
BoardChrysa Mineo(Director)Jack Florio(Director)Elaine Heron(Director)Santosh Vetticaden(Director)Karen Talmadge(Director)
Board seatAnand Mehra· per SEC Form D · $102.7M raise · filed Jan 2020
Co-investorsNew Enterprise Associates (NEA)Pappas CapitalRiverVest Venture PartnersSofinnova Ventures
Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.
BiotechDigital HealthHealthtechMedical DevicesDublin, US
Michael W. Dunne(Executive Officer, Promoter)Corey N. Fishman(Executive Officer, Director, Promoter)Judith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)
BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)
Board seatJames I. Healy· per SEC Form D · $47.6M raise · filed Dec 2016
Co-investorsBay City CapitalCanaan PartnersSofinnova VenturesFrazier Life Sciences
BiotechHamilton
Brenton K. Ahrens(Director)James I. Healy(Director)Mark Chin(Director)Patrick J. Heron(Director)inRonald M. Hunt(Director)Shahzad Malik(Director)
Board seatJames I. Healy· per SEC Form D · $51.6M raise · filed Jan 2020
Co-investorsFrazier Life Sciences
HealthtechSan Francisco, US
Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)Leon Chen, Ph.D.(Director)Carol Gallagher(Director)Joshua Resnick, M.D.(Director)
Board seatMichael Powell· per SEC Form D · $62M raise · filed Dec 2017
Co-investorsMission Bay CapitalMission BiocapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sofinnova Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
IPOs and acquisitions across the tracked portfolioAclaris TherapeuticsNASDAQ: ACRS
Portfolio news
latest coverage across their companiesAclaris Therapeutics · investing.com · May 8, 2026
Frequently asked questions
- Where is Sofinnova Venture Partners located?
- Sofinnova Venture Partners is headquartered in Menlo Park, US.